synthetic tumor-associated peptide vaccine therapy

BIOLOGICAL2 trials

Conditions

HER2-positive Breast CancerMale Breast CancerMetastatic Colorectal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerStage IV Colorectal Cancer AJCC v7

Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Enrolling by invitationNCT02600949

M.D. Anderson Cancer CenterMetastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IVA Colorectal Cancer AJCC v7 +3

Start: 2016-05-11End: 2027-05-31Target: 300Updated: 2026-06-17

Phase 2

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

CompletedNCT00343109

University of WashingtonHER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer +2

Start: 2004-03-31Updated: 2020-02-12

Related Papers

Abstract CT091: Trial in progress: A phase I study of personalized neoantigen vaccination combined with PD-1 blockade and CD40 agonism in resected pancreatic ductal adenocarcinoma

Cancer Research2026-04-17

synthetic tumor-associated peptide vaccine therapy

Sponsors

Conditions

Phase 1

Phase 2

Related Papers